STONY BROOK, N.Y., April 25, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio (the “Project”). The Project seeks [...]
STONY BROOK, N.Y. – April 22, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. Applied DNA common stock [...]
STONY BROOK, N.Y., and JUPITER, F.L. March 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of specialty enzymes used in the life sciences sector, have entered into an agreement under which [...]
STONY BROOK, N.Y., March 14, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 – 4, 2024. Applied DNA sales team members will be available during the [...]
There is growing clamour from the US apparel and textile industry to boost enforcement of the Uyghur Forced Labor Prevention Act (UFLPA), however there are a number of challenges that need to be overcome first for verifying cotton's origin, writes Robert P. Antoshak, Gherzi Textile Organization partner and MeiLin Wan, vice president, Applied DNA [...]
STONY BROOK, NY / ACCESSWIRE / February 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its first fiscal quarter ended December 31, 2023. The Company’s Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. “We made substantial progress in advancing [...]
STONY BROOK, N.Y. February 5, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host [...]
STONY BROOK, N.Y., January 31, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the “Holders”) for the issuance and sale of an aggregate of 5,644,061 of its shares of common [...]
STONY BROOK, N.Y., and NEEDHAM, M.A. - December 14, 2023 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Kudo Biotechnology (Kudo Bio), a leading global mRNA CDMO offering end-to-end cGMP mRNA manufacturing solutions, today announced their entry into a joint development agreement (the “JDA”) to [...]